Soleus Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.13M Sell
672,039
-227,961
-25% -$829K 0.08% 76
2026
Q2
$3.51M Sell
900,000
-150,000
-14% -$558K 0.12% 80
2026
Q1
$4.02M Buy
+1,050,000
New +$4.19M 0.16% 68

Other funds holding SABS

Soleus Capital Management's SABS Position: Q3 2026 in Review

Soleus Capital Management reduced its SAB Biotherapeutics (SABS) stake by 25% in Q3 2026, selling an estimated $829K and leaving 672,039 shares worth $2.13M. The position accounts for 0.08% of the portfolio, ranked #76.

Soleus Capital Management first reported a position in SABS in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.02M in Q1 2026. 100 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Soleus Capital Management held 672,039 shares of SAB Biotherapeutics worth $2.13M as of Q3 2026.
  • Soleus Capital Management sold 227,961 SAB Biotherapeutics shares in Q3 2026, an estimated $829K.
  • SAB Biotherapeutics made up 0.08% of Soleus Capital Management's portfolio in Q3 2026, its #76 holding.
  • Soleus Capital Management first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • Soleus Capital Management's SAB Biotherapeutics position peaked at $4.02M in Q1 2026.
  • 100 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Soleus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.